` CTX (Captor Therapeutics SA) vs WIG20 Comparison - Alpha Spread

C
CTX
vs
W
WIG20

Over the past 12 months, CTX has outperformed WIG20, delivering a return of +52% compared to the WIG20's +33% growth.

Stocks Performance
CTX vs WIG20

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CTX vs WIG20

Performance Gap Between CTX and WIG20
HIDDEN
Show

Performance By Year
CTX vs WIG20

Loading
CTX
WIG20
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Captor Therapeutics SA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Captor Therapeutics SA
Glance View

Market Cap
453.5m PLN
Industry
N/A

Captor Therapeutics SA engages in the development of protein degradation drugs for cancer and autoimmune diseases. The company is headquartered in Wroclaw, Woj. Dolnoslaskie and currently employs 98 full-time employees. The company went IPO on 2021-04-19. The firm works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The firm covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.

CTX Intrinsic Value
HIDDEN
Show
Back to Top